HTTIF (HighTide Therapeutics) ROE % Adjusted to Book Value: -15.46% (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.35
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics ROE % Adjusted to Book Value?

HighTide Therapeutics HTTIF 14 ROE % Adjusted to Book Value is -15.46% as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

HighTide Therapeutics's ROE % for the quarter that ended in Dec. 2025 was -72.53%. HighTide Therapeutics's PB Ratio for the quarter that ended in Dec. 2025 was 4.69. HighTide Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -15.46%.

HighTide Therapeutics ROE % Adjusted to Book Value Related Terms

HighTide Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics ROE % Adjusted to Book Value Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00 -13.80

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 -15.46

HTTIF vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, HighTide Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's ROE % Adjusted to Book Value falls into.


HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics ROE % Adjusted to Book Value Calculation

HighTide Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-64.71% / 4.69
=-13.80%

HighTide Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-72.53% / 4.69
=-15.46%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -15.46% mean?
HighTide Therapeutics (HTTIF) has a ROE % Adjusted to Book Value of -15.46% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on HighTide Therapeutics and its competitors.
Is HighTide Therapeutics' ROE % Adjusted to Book Value too high?
HighTide Therapeutics' current ROE % Adjusted to Book Value is -15.46%. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' ROE % Adjusted to Book Value compare to VRTX and REGN?
HighTide Therapeutics' ROE % Adjusted to Book Value of -15.46% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on HighTide Therapeutics and its competitors. HighTide Therapeutics's current ROE % Adjusted to Book Value is -15.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current ROE % Adjusted to Book Value of -15.46%. The current ROE % Adjusted to Book Value is -15.46%. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current ROE % Adjusted to Book Value is -15.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price